Skip to main content

Waldenstrom Macroglobulinemia clinical trials at UCSD

6 in progress, 2 open to eligible people

Showing trials for
  • Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

    open to eligible people ages 18 years and up

    Study consists of two main parts to explore BGB-16673 recommended dosing, a Part 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a part 2 (dose expansion cohorts)

    La Jolla, California and other locations

  • Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

    La Jolla, California and other locations

  • PCI-32765 (Ibrutinib)

    Sorry, accepting new patients by invitation only

    The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

    La Jolla, California and other locations

  • CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

    Sorry, in progress, not accepting new patients

    CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety and tolerability of CLBR001 + SWI019 and is designed to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD). Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019. The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019.

    San Diego, California and other locations

  • Patients Treated With CLBR001 CAR-T

    Sorry, accepting new patients by invitation only

    This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells

    San Diego, California and other locations

  • Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

    Sorry, not currently recruiting here

    This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lymphoma.

    La Jolla, California and other locations

Last updated: